The Research Service Voucher provides rapid funding of up to EUR 5,000 in expenses for purchasing core services, technology/equipment, and other resources in support of rheumatic and musculoskeletal (RMD) research projects. The goal is to give investigators with limited research funds the support they need to nurture a small idea with big potentialthat could lead to larger subsequent funding or aid in completing a funded and impactful RMD project. Researchers can either:
-Add new data collection to an existing (“parent”) RMD project to develop new research that is distinct from the aims of the parent project.
-Collect information de novo, outside the context of an existing project, to support the development of new RMD research.
Budget and financial requirements
-The budget may not exceed EUR 5,000 per project (with only listings of direct costs).
-If awarded a voucher, all funds will need to be spent within 12 months of account establishment.
-Cost sharing and attempts to raise funds from other sources are encouraged.
Application requirements
-Applicants must justify their needs for a research voucher and indicate how the coverage of costs will contribute to their research outcomes.
-Awardees will be required to present proof-of-payment as outlined in the budget and complete the follow-up impact survey.
1. Strong relevance to rheumatic and musculoskeletal diseases (RMDs)
The most competitive applications directly address:
Clear alignment with EULAR’s RMD mission is essential.
2. Strong translational and patient-care impact
EULAR reviewers strongly favor projects likely to:
Clinical applicability is one of the strongest predictors of competitiveness.
3. Strong methodological rigor
Competitive applications generally demonstrate:
Weak methodology is a major reviewer concern across EULAR funding schemes.
4. Multinational and multidisciplinary collaboration
High-scoring applications often involve:
EULAR strongly values pan-European collaboration and knowledge exchange.
5. Strong preliminary or pilot data
Successful proposals frequently include:
Even smaller EULAR “voucher” programs prioritize projects with credible feasibility evidence.
6. Patient-centered and implementation-focused research
EULAR increasingly prioritizes:
Projects with direct practice implications often perform strongly.
7. Strong international training and networking potential
For fellowships and exchange grants, reviewers heavily assess:
EULAR strongly supports educational visits, scientific exchange, and international cooperation.
8. Innovation balanced with feasibility
Competitive applications usually combine:
with realistic execution plans.
Overly ambitious proposals without clear feasibility often score poorly.
9. Strong publication and academic track record
Important predictors include:
Research productivity strongly influences reviewer confidence.
10. Potential for future larger European funding
Reviewers favor projects likely to:
EULAR funding is frequently viewed as seed or developmental support.
Frequent reviewer concerns include:
Researchers and Health Professionals from all EULAR-affiliated countries.
-Although the primary metric for evaluation will be the quality of the proposal, in the event of over-subscription and otherwise equitable adjudication of merit, weighting will be given to those applications coming from regions in which rheumatology research has received lower levels of research support on a historical basis, or that has been under-represented in abstract submission rates to the EULAR Congress.
-Investigators are eligible to receive one voucher award per year. Only one application per research group per cycle will be accepted.
Sponsor Institute/Organizations: European Alliance of Associations for Rheumatology (EULAR)
Sponsor Type: Corporate/Non-Profit
Address: Seestrasse 240 CH 8802 Kilchberg (Zurich)
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Q1 2026: March 31, 2026
Q2 2026: June 30, 2026
Q3 2026: September 30, 2026
Q4 2026: December 31, 2026
$5,850
Affiliation: European Alliance of Associations for Rheumatology (EULAR)
Address: Seestrasse 240 CH 8802 Kilchberg (Zurich)
Website URL: https://www.eular.org/eular-research-funding
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.